FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer.

Animals Humans Cell Line, Tumor Cell Movement Disease Models, Animal Epithelial-Mesenchymal Transition / genetics Gene Expression Regulation, Neoplastic MicroRNAs / genetics Neoplasm Metastasis Transcription Factor AP-1 / metabolism Triple Negative Breast Neoplasms / pathology Tumor Microenvironment
AP-1 transcription factors EMT FOSL1 FRA-1 TNBC

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
05 May 2023
Historique:
received: 21 02 2023
revised: 21 04 2023
accepted: 01 05 2023
medline: 15 5 2023
pubmed: 13 5 2023
entrez: 13 5 2023
Statut: epublish

Résumé

Among FOS-related components of the dimeric AP-1 transcription factor, the oncoprotein FRA-1 (encoded by

Identifiants

DOI: 10.3390/ijms24098307 PMID: 37176013 PMC: PMC10179602
pubmed: 37176013
pii: ijms24098307
doi: 10.3390/ijms24098307
pmc: PMC10179602
pii:
doi:

Substances chimiques

MicroRNAs 0
Transcription Factor AP-1 0
fos-related antigen 1 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Clin Exp Pathol. 2014 May 15;7(6):3008-17
pubmed: 25031719
Cancer Cell. 2003 Jul;4(1):67-79
pubmed: 12892714
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Nat Commun. 2020 Apr 14;11(1):1787
pubmed: 32286297
Cancer Res. 2001 Jul 1;61(13):5168-78
pubmed: 11431356
Cancer Lett. 2021 May 28;506:23-34
pubmed: 33652085
Nucleic Acids Res. 2013 Jul;41(13):6618-36
pubmed: 23677615
Breast Cancer Res. 2018 Jan 30;20(1):9
pubmed: 29382358
EBioMedicine. 2021 Feb;64:103231
pubmed: 33517076
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Front Pharmacol. 2022 Mar 25;13:843358
pubmed: 35401168
Nat Cell Biol. 2015 Sep;17(9):1218-27
pubmed: 26258633
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9
pubmed: 20080645
Mol Cell Biol. 2014 Aug;34(16):2961-80
pubmed: 24891615
Cancer Lett. 2020 Jan 28;469:256-265
pubmed: 31672492
Dev Cell. 2021 Dec 6;56(23):3203-3221.e11
pubmed: 34847378
PLoS One. 2016 Mar 01;11(3):e0147489
pubmed: 26930581
Front Oncol. 2022 Aug 18;12:974523
pubmed: 36059653
Oncotarget. 2019 Apr 5;10(27):2586-2606
pubmed: 31080552
Cell Death Differ. 2015 Feb;22(2):336-50
pubmed: 25301070
BMC Cancer. 2013 Sep 28;13:441
pubmed: 24073962
Cancer Cell Int. 2020 Nov 26;20(1):569
pubmed: 33292221
Oncogene. 2014 Mar 6;33(10):1316-24
pubmed: 23474758
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17396-401
pubmed: 17090666
J Cancer. 2021 Sep 9;12(21):6543-6552
pubmed: 34659545
PLoS Genet. 2012;8(5):e1002723
pubmed: 22654675
Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2550-2561
pubmed: 30354251
Mol Cell. 2010 Apr 9;38(1):114-27
pubmed: 20385094
Cancer Res. 2011 Jul 1;71(13):4707-19
pubmed: 21555371
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
EMBO J. 2021 Sep 15;40(18):e108647
pubmed: 34459003
Cell Cycle. 2010 Jul 1;9(13):2483-4
pubmed: 20543576
Oncogene. 2013 Sep 5;32(36):4294-303
pubmed: 23001043
Oncogene. 2020 Jun;39(23):4491-4506
pubmed: 32385348
Science. 2021 Aug 20;373(6557):871-876
pubmed: 34282049
Nat Cell Biol. 2022 Apr;24(4):554-564
pubmed: 35411083
J Virol. 2010 Feb;84(3):1376-86
pubmed: 19923172
Breast Cancer Res. 2014 Aug 22;16(4):428
pubmed: 25677449
Nucleic Acids Res. 2014;42(17):11011-24
pubmed: 25200076
Cell. 2008 Nov 28;135(5):865-78
pubmed: 19041750
Oncogene. 2015 Aug 20;34(34):4421-8
pubmed: 25381818
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7353-7362
pubmed: 30910979
Int J Mol Sci. 2022 Jan 28;23(3):
pubmed: 35163444
J Med Chem. 2022 Nov 24;65(22):15374-15390
pubmed: 36358010
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):151-157
pubmed: 29997040
Nat Commun. 2018 Apr 13;9(1):1466
pubmed: 29654229
Int J Cancer. 1999 Oct 22;84(5):533-8
pubmed: 10502734
Oncogene. 2014 Jun 5;33(23):3075-82
pubmed: 23873024
Science. 2021 Dec 10;374(6573):eabm4805
pubmed: 34762488
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Oncogene. 2013 Aug 1;32(31):3606-15
pubmed: 22926518
RSC Chem Biol. 2021 Jan 29;2(2):656-668
pubmed: 34458807
Clin Cancer Res. 2017 Jun 1;23(11):2806-2816
pubmed: 27923843
Cell. 2014 Jul 3;158(1):171-84
pubmed: 24954536
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
J Exp Clin Cancer Res. 2019 Jul 16;38(1):313
pubmed: 31311575
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
Oncogenesis. 2017 Jun 12;6(6):e345
pubmed: 28604765
Nat Commun. 2017 Feb 21;8:14294
pubmed: 28220783
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18295-18303
pubmed: 31451668
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):11-23
pubmed: 31034924
Trends Cancer. 2020 Sep;6(9):775-780
pubmed: 32312682
Cancer Res. 2014 Jul 15;74(14):3983-94
pubmed: 24830720
Cancer Cell. 2014 Feb 10;25(2):210-25
pubmed: 24525235
J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73
pubmed: 15564374
Nat Genet. 2018 Dec;50(12):1705-1715
pubmed: 30349115
Biomed Pharmacother. 2022 Jun;150:113037
pubmed: 35658206
Cancer Res. 2017 Aug 1;77(15):3982-3989
pubmed: 28428275
Sci Signal. 2017 Jun 13;10(483):
pubmed: 28611183
Cancer Res. 2009 Dec 15;69(24):9228-35
pubmed: 19920183
Sci Rep. 2016 Feb 24;6:21903
pubmed: 26906973
Cancer Res. 2018 Jan 15;78(2):387-398
pubmed: 29187406
Cell Death Differ. 2020 Jan;27(1):255-268
pubmed: 31114028
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Oncogene. 2022 Feb;41(6):907-919
pubmed: 34992218
Sci Signal. 2011 Jun 14;4(177):ra41
pubmed: 21673316
Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444
pubmed: 34791371
Cancers (Basel). 2022 Mar 14;14(6):
pubmed: 35326630
Elife. 2021 Aug 17;10:
pubmed: 34399888
Eur J Cancer. 2005 Nov;41(16):2449-61
pubmed: 16199154
Mol Cell. 2013 Jan 24;49(2):249-61
pubmed: 23219535
Mol Cell Biol. 1998 Dec;18(12):7095-105
pubmed: 9819396
Clin Cancer Res. 2008 Feb 15;14(4):1050-8
pubmed: 18281537
Development. 2000 Nov;127(22):4937-48
pubmed: 11044407
Sci Rep. 2017 Sep 18;7(1):11768
pubmed: 28924209
Oncogene. 2012 Apr 26;31(17):2237-46
pubmed: 21909135
Oncogene. 2019 Jul;38(28):5725-5738
pubmed: 31015574
Oncotarget. 2013 Aug;4(8):1293-308
pubmed: 23945276
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44
pubmed: 23483055
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Cancer. 2022 Feb;3(2):232-250
pubmed: 35221336
J Cell Biol. 2007 Jul 30;178(3):425-36
pubmed: 17664334
Oncogene. 2012 Mar 22;31(12):1493-503
pubmed: 21822309
Cell Signal. 2010 Jun;22(6):894-9
pubmed: 20060892
Br J Cancer. 2017 Aug 22;117(5):675-684
pubmed: 28683467
Nat Cell Biol. 2007 Aug;9(8):932-44
pubmed: 17643117
Cell Cycle. 2007 Nov 1;6(21):2633-9
pubmed: 17957143
Nat Commun. 2021 Nov 1;12(1):6276
pubmed: 34725325
Cancers (Basel). 2022 Jul 29;14(15):
pubmed: 35954358
FASEB J. 2018 Jan;32(1):276-288
pubmed: 28899878
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
Oncogene. 2010 Feb 4;29(5):662-73
pubmed: 19966854
Nat Rev Cancer. 2020 Jun;20(6):303-322
pubmed: 32300195
Biosci Rep. 2021 Feb 26;41(2):
pubmed: 33443534
Breast Cancer Res Treat. 2008 Feb;107(3):337-47
pubmed: 17393299
Mol Cell Biol. 2009 Oct;29(20):5488-504
pubmed: 19687301
Cell Adh Migr. 2013 Sep-Oct;7(5):408-11
pubmed: 24084233
Nat Cell Biol. 2002 May;4(5):E131-6
pubmed: 11988758
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
Cancer Cell. 2013 Sep 9;24(3):347-64
pubmed: 24029232
Mol Immunol. 2008 Jan;45(1):137-43
pubmed: 17572495
Nat Struct Mol Biol. 2020 Jun;27(6):521-528
pubmed: 32514177
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Oncogene. 2014 Jun 5;33(23):3014-23
pubmed: 23831570
Oncogene. 2004 May 27;23(25):4466-76
pubmed: 15064752
Dev Cell. 2020 Sep 14;54(5):593-607.e5
pubmed: 32668208
Mol Biol Rep. 2020 Jan;47(1):737-752
pubmed: 31612408
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Oncotarget. 2015 Apr 10;6(10):7804-14
pubmed: 25762639
Nat Genet. 2008 May;40(5):499-507
pubmed: 18443585
Cancer Metastasis Rev. 2016 Dec;35(4):547-573
pubmed: 28025748
Cancer Res. 2014 Mar 1;74(5):1566-75
pubmed: 24413534
Gene. 2006 Sep 1;379:1-11
pubmed: 16784822
J Cell Biochem. 2018 Jun;119(6):4945-4956
pubmed: 29384218
Oncotarget. 2017 Mar 15;8(13):20572-20587
pubmed: 28411283
Cancer Res. 2009 Aug 15;69(16):6624-32
pubmed: 19654313
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2337-E2346
pubmed: 28270621
PLoS Genet. 2014 May 22;10(5):e1004323
pubmed: 24852022
Oncogene. 2017 Feb 16;36(7):942-955
pubmed: 27452518
Nat Cell Biol. 2004 Oct;6(10):931-40
pubmed: 15448698
Sci Rep. 2020 Mar 13;10(1):4681
pubmed: 32170125
Oncogene. 2012 Nov 22;31(47):4889-97
pubmed: 22286759
Mol Cancer Res. 2019 Oct;17(10):1999-2014
pubmed: 31300541
Genes Dev. 2020 Feb 1;34(3-4):179-193
pubmed: 31879358
Front Immunol. 2021 Oct 12;12:701675
pubmed: 34712224
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10
pubmed: 23509284
Cancer Cell. 2018 Nov 12;34(5):807-822.e7
pubmed: 30423298
Mol Cell Biol. 2007 Jun;27(11):3936-50
pubmed: 17371847
Cell. 2009 Sep 18;138(6):1122-36
pubmed: 19766566
Semin Cancer Biol. 2022 Nov;86(Pt 3):18-31
pubmed: 35643219
Nat Rev Cancer. 2007 Dec;7(12):899-910
pubmed: 18004397
BMC Cancer. 2019 Jul 27;19(1):738
pubmed: 31351450
Nucleic Acids Res. 2021 Mar 18;49(5):2488-2508
pubmed: 33533919
J Cancer. 2019 Aug 28;10(21):5223-5233
pubmed: 31602273
EMBO J. 2020 Sep 1;39(17):e103209
pubmed: 32692442
Sci Rep. 2018 Jan 8;8(1):73
pubmed: 29311580
Nat Rev Cancer. 2021 May;21(5):325-338
pubmed: 33547455
Cell Res. 2010 Jun;20(6):701-12
pubmed: 20386569
Cell. 2006 Oct 6;127(1):139-55
pubmed: 17018282
Science. 2016 Mar 4;351(6277):aad3680
pubmed: 26941323
Biochem Pharmacol. 2018 Jun;152:104-113
pubmed: 29574069
Mol Cancer Res. 2007 May;5(5):485-96
pubmed: 17510314
Histol Histopathol. 2000 Jul;15(3):921-8
pubmed: 10963134
Oncogene. 2005 Feb 17;24(8):1434-44
pubmed: 15608675
Cell Death Dis. 2018 Dec 5;9(12):1171
pubmed: 30518916
Oncogene. 2008 Oct 9;27(46):5988-6001
pubmed: 18641685
Cancer Lett. 2017 Jan 28;385:97-107
pubmed: 27816489
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166

Auteurs

Laura Casalino (L)

Institute of Genetics and Biophysics "A. Buzzati Traverso", Consiglio Nazionale delle Ricerche (CNR), Via Pietro Castellino, 111, 80131 Naples, Italy.
ORCID: 0000-0002-2557-0443

Francesco Talotta (F)

Institute of Genetics and Biophysics "A. Buzzati Traverso", Consiglio Nazionale delle Ricerche (CNR), Via Pietro Castellino, 111, 80131 Naples, Italy.

Ilenia Matino (I)

Institute of Genetics and Biophysics "A. Buzzati Traverso", Consiglio Nazionale delle Ricerche (CNR), Via Pietro Castellino, 111, 80131 Naples, Italy.

Pasquale Verde (P)

Institute of Genetics and Biophysics "A. Buzzati Traverso", Consiglio Nazionale delle Ricerche (CNR), Via Pietro Castellino, 111, 80131 Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Phénomènes physiologiques › Mouvement cellulaire › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transdifférenciation cellulaire › Transition épithélio-mésenchymateuse › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Facteur de transcription AP-1 › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › FRA-1 as a Regulator of EMT and Metastasis in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › FRA-1 as a Regulator of EMT and Metastasis in...